News
Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...
When treating obesity, semaglutide may be associated with a reduced fracture risk compared with sleeve gastrectomy.
A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...
In a retrospective cohort study using propensity matching, among patients with obesity, those taking semaglutide had lower ...
The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...
A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...
Explore more
Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.
Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...
Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...
Semaglutide is associated with a high prevalence of adverse events, and its long-term safety is unknown. In an observational ...
Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of semaglutide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results